TY - JOUR
T1 - Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy
T2 - The STAR 3 experience
AU - Buse, John B.
AU - Dailey, George
AU - Ahmann, Andrew A.
AU - Bergenstal, Richard M.
AU - Green, Jennifer B.
AU - Peoples, Tim
AU - Tanenberg, Robert J.
AU - Yang, Qingqing
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.
AB - Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.
UR - http://www.scopus.com/inward/record.url?scp=79957598950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957598950&partnerID=8YFLogxK
U2 - 10.1089/dia.2010.0225
DO - 10.1089/dia.2010.0225
M3 - Article
C2 - 21488717
AN - SCOPUS:79957598950
SN - 1520-9156
VL - 13
SP - 601
EP - 606
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 6
ER -